Efficacy of pegaspargase and pediatric treatment protocols for young adults with acute lymphoblastic leukemia
Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 89-95
DOI: 10.24287/j.1122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Timur T. Valiev. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
With current treatment protocols for acute lymphoblastic leukemia (ALL), a 7-year overall survival (OS) of 91% can be achieved in pediatric patients and a 3-year OS of 64% in adults. However, there is a group of young adult patients (aged 19–39 years), for whom treatment approaches are currently under investigation. The key question for researchers is whether to treat young adults with ALL using pediatric or adult protocols. Aim: to study the efficacy and toxicity of the ALL-IC BFM 2002 protocol in young adults with ALL. Materials and methods. Between 01.11.2003 and 12.10.2021, 22 patients aged 18–21 years with newly diagnosed ALL were included in this retrospective/prospective study and treated according to the ALL-IC BFM 2002 protocol for pediatric patients. There were 12 (54.5%) males and 10 (45.5%) females. Of these, 2 (9.1%) were diagnosed with T-ALL and 20 (90.9%) with B-ALL. Based on the protocol risk criteria, 8 (36.4%) patients were stratified into the standard-risk group and 14 (63.6%) into the intermediate-risk group. To assess treatment efficacy, we analyzed remission rates, OS, relapse-free survival and event-free survival. To assess treatment toxicity depending on the asparaginase formulation used (pegylated vs. native), the NCI CTCAE (version 2.0) was applied.
Results
Complete remission on day 33 of induction was achieved in 100% of the patients. No cases of induction death, death in remission, or refractory ALL were registered. The 7-year OS was 86.2 ± 9.1% and the 7-year relapse-free survival was 62.4 ± 12.6%. All treatment failures (n = 8) were ALL relapses. Toxicity analysis revealed that the incidence of hypersensitivity reactions, hyperlipidemia, hyperglycemia, and grade III–IV hepatotoxicity was lower in the patients treated with pegaspargase than in those receiving native L-asparaginase (р 0.05).
Conclusion
In young adults treated according to the ALL-IC BFM 2002 protocol, the 7-year OS reached 86.2 ± 9.1%. This treatment protocol has good tolerability and an acceptable toxicity profile.
Zitieren
APA
Valiev, T. T. (2026). Efficacy of pegaspargase and pediatric treatment protocols for young adults with acute lymphoblastic leukemia. Pediatric Hematology/Oncology and Immunopathology, 25(2), 89-95. https://doi.org/10.24287/j.1122
Vancouver
Valiev TT. Efficacy of pegaspargase and pediatric treatment protocols for young adults with acute lymphoblastic leukemia. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):89-95. doi:10.24287/j.1122
BibTeX
@article{Valiev2026,
author = {Valiev, Timur T.},
title = {Efficacy of pegaspargase and pediatric treatment protocols for young adults with acute lymphoblastic leukemia},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {2},
pages = {89--95},
doi = {10.24287/j.1122}
}
EUVIMED